Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Bevacizumab Plus Etoposide for Patients With Recurrent Malignant Glioma

NCT00612430 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00612430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00612430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Bevacizumab Plus Etoposide for Patients With Recurrent Malignant Glioma
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
September 30, 2011
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, gliosarcoma